Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roger Echols

Showing results (51-60 of 51) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 51 results.
The Lancet. Infectious Diseases|October 15, 2020
Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trialMatteo Bassetti, Roger Echols, Yuko Matsunaga, et al.
Pageof 6

Showing results (51-60 of 51) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 51 results.
The Lancet. Infectious Diseases|October 15, 2020
Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trialMatteo Bassetti, Roger Echols, Yuko Matsunaga, et al.
Pageof 6